ABSTRACT
INTRODUCTION
Carcinoma prostate is the second most common cancer in men worldwide. About 50% patients have metastatic disease at the time of diagnosis and nearly all patients (85-100%) who die of prostate carcinoma have skeletal metastases. The most commonly involved bones are vertebral column, ribs, skull and proximal ends of the long bones (1) .
Skeletal scintigraphy shows very high sensitivity in the detection of metastatic disease from prostate cancer due to osteoblastic nature of the lesion (2) . Bone scan requires a gamma camera and a bone seeking radiopharmaceutical e.g. On the other hand, diagnosis of bone metastases is usually made by the presence of multiple focal lesions distributed randomly in the skeleton. But a solitary lesion in a patient with known malignancy has a significant chance of being metastatic. If the lesion is in the spine or pelvis, the risk of malignancy is about 60 -70%, in case of skull the risk is 40-50%, and if in rib the chance of malignancy is 10 to 20%. Other than being metastatic, a solitary abnormality also has the possibility to be a primary bone tumor, arthritis, trauma, enchondroma, osteoma, fibrous dysplasia, osteomyelitis or monostotic Paget disease (2) . Moreover, the mean age of presentation for carcinoma prostate is 70 years which is also the usual age group for having degenerative change and fractures (4) . To make an accurate interpretation in such diverse presentation, we take help from patient history and other investigations. Often the only certain way to establish the etiology is biopsy which is not only invasive but also may be very difficult to perform from a lesion in the axial skeleton. So it would be helpful if bone scintigraphy itself could provide a quantitative clue to the underlying pathology.
For a radionuclide bone scan 99m Tc MDP is administered intravenously, and then it undergoes protein binding in blood which increases to about 50% at 4 hours after injection. Only unbound tracers are available for bone uptake. 99mTc MDP undergoes passive diffusion through the capillary wall into the extravascular space and then binds to bone by physicochemical adsorption (chemisorption) to the hydroxyapatite structure of bone tissue. The net exchange of a substance between blood and tissue depends on blood flow, surface area and the capillary permeability (5) . There are significant differences in the histological structure and metabolic handling of radiopharmaceuticals between the normal and diseased bone (6) . This is what researchers tried to exploit in developing more objective methods to separate metastatic lesions from degenerative and other changes using bone scintigraphy.
Metastatic bone is mainly composed of woven bone which has a greater surface area than normal lamellar bone.
Besides, the crystalline structure of hydroxyapatite in this newly formed bone is amorphous and biphosphonate compounds have significantly higher adsorption on amorphous calcium phosphate (6) . This microarchitecture, high blood flow, and increased transcapillary migration all work together to result in rapid as well as intense radiotracer concentration in the metastatic lesions (7). But degenerative bone changes have increased amounts of lamellar bone which accounts for the relatively lower radiotracer uptake. This is supported by the work of Israel et al. (6) , who found the 4-hour lesion-to-nonlesion uptake ratio in degenerative joint disease to be significantly lower than that of metastases. They showed that 24/4 hour ratio of 99m Tc MDP uptake in bone metastasis and degenerative changes had significant different values and suggested that this ratio might be useful in cancer patients whose bone scans demonstrate solitary lesion. Later, scintimetric characterization by 4/24 hour retention ratio was devised by Dr. V. Siva et al. (8) . Bone scans were done in both anterior and posterior views at 4 and 24 hours. The focal hot spots in the processed images were identified and the maximum counts were calculated by drawing the region of interest over the skeletal hot spots. Then Dr. V. Siva's retention ratio was calculated by dividing the 4-hour count with 24-hour count. It was found that malignant (metastatic) lesion showed the value greater than 10, degenerative lesions 5-10, and the benign lesions less than 5. This method was applied on delayed union of skeletal fractures where pathological fracture group obtained the mean value of 12.5 ± 3.1 and the benign group had the mean value of 6.68 ± 2.8 (9) . Recently a study done on prostate cancer patients in Southern India found the mean of 4/24 hour Dr. V. Siva's retention ratio to be 11.5 ± 2.8 in case of metastatic disease from carcinoma prostate (8) . This ratio might be a valuable noninvasive tool for identifying the underlying pathology, especially in doubtful cases.
This study was performed to evaluate the V. Siva's ratio in a small sample of prostate cancer patients in Bangladeshi population. 
PATIENTS AND METHODS

RESULTS
Total 32 carcinoma prostate patients age mean ± SD, 67 Total 132 skeletal hot spots were identified, out of which 89 were reported as metastatic and 43 as degenerative. The mean V. Siva's ratio of metastatic group was 9.3 ± 2.2 (95% CI 8.5-10.1) and that of degenerative group was 8.2 ± 2.0 (95% CI 7.5-8.9). Statistically significant difference was observed between the two groups (Table 1.) Among the four solitary lesions, three were metastatic and had the ratio above 10. On the other hand, the only degenerative lesion was noted in left knee joint with V. Siva's ratio of 6.95 (Table 2. ).
Table 2: Distribution of V. Siva's ratio in solitary lesion patients
Seventeen out of 32 patients were symptomatic (complained pain) and 80 skeletal hot spots were reported in them. Among those, 61 were reported as metastatic and their mean V. Siva's ratio was 9.64 ± 2.2. A total of 19 hot spots were reported as degenerative and their mean V. Siva's ratio was 8.69 ± 2.3. The difference was not statistically significant between two groups (Table 3) . Degenerative hot spots were 24 in number and their mean V. Siva's ratio was 7.93 ± 1.6. The difference was not statistically significant between two groups (Table 4.).
Table 4: Distribution of the skeletal hot spots in asymptomatic patients
Total number of metastatic hot spots was 89, out of which 28 were found in patients with S. PSA level less than or equal to 20 ng/ml. Their mean V. Siva's ratio was 9.81 ± 2.7. Remaining 61 lesions were found in patients with S. PSA level > 20 ng/ml. Their mean V. Siva's ratio was 9.13 ± 2. The difference was not statistically significant (p > 0.05) between two groups (Table 5 ). Siva's ratio of the study patients (Figure 1 ). Probably this is why no correlation was found between S.
PSA and V. Siva's ratio of the study patients in the current study.
CONCLUSION
Management protocol for patients with prostate cancer depends to a large extent on the absence or presence of skeletal metastases. Imaging of metastases in carcinoma prostate is often a challenge and even though there are currently several new imaging modalities for the detection of skeletal metastases, the age old nuclear medicine bone scintigraphy has proved to be the mainstay due to its high sensitivity, low cost and easy availability. However, it suffers from relative low specificity and the differentiation of true metastasis from a benign bone lesion is sometimes very difficult. Dr. V. Siva's retention ratio for this purpose was reported to be useful. In the present study, the same V. Siva's retention ratio protocol applied on a small number of prostate cancer patients in Bangladesh gave promising results.
The V. Siva's retention ratio of metastatic skeletal hot spots was found to be 9.3 and that of degenerative hot spots 8.2. The difference was statistically significant. Therefore, it may be concluded that the inclusion of V Siva's quantitative parameter in adjunct to conventional bone scintigraphy for the skeletal survey of carcinoma prostate patients can help to narrow down the specificity spectrum of bone scan hot spots being either due to metastasis versus benign disease.
